

molecule comprising a DNA sequence selected from the group consisting of:

- (a) nucleotide #571 or #577 to #882 of SEQ ID NO: 1;
- (b) a naturally occurring allelic variant of (a); and
- (c) a sequence degenerate to (a) or (b).

47. A host cell transformed with the DNA molecule of claim 46.

48. A vector comprising a DNA molecule of claim 46 in operative association with an expression control sequence therefor.

49. A host cell transformed with the vector of claim 48.

50. A method for producing a purified V1-1 protein, said method comprising the steps of:

- (a) culturing a host cell transformed with a DNA molecule according to claim 42; and
- (b) recovering and purifying said V1-1 protein from the culture medium.

51. A method for producing a purified V1-1 protein said method comprising the steps of:

- (a) culturing a host cell transformed with a DNA molecule according to claim 43; and
- (b) recovering and purifying said V1-1 protein from the culture medium.

52. A method for producing a purified V1-1 protein said method comprising the steps of:

- (a) culturing a host cell transformed with a DNA molecule according to claim 46; and

(b) recovering and purifying said V1-1 protein from the culture medium.

53. A chimeric DNA molecule comprising a DNA sequence encoding a propeptide from a member of the BMP family of proteins linked in correct reading frame to the DNA sequence of claim 42.

54. A chimeric DNA molecule according to claim 53, wherein the propeptide is the propeptide from BMP-2.

REMARKS

Applicants have cancelled claims 29-41 and substituted new claims 42 to 54 in order to more particularly describe and distinctly claim the invention. The new claims describe novel DNA molecules which encode a polypeptide demonstrated in the specification to induce the formation of tendon/ligament-like tissue. No new matter has been added to the claims. Accordingly, the amendment is proper and should be entered. For the reasons stated below, the newly submitted claims are not subject to the previous rejections, and should be allowed.

Applicants acknowledge the Examiner's withdrawal of the double patenting rejection over application serial no. 08/164,102.

Claims 29-32, 37, 38, 40 and 41 were rejected under 35 U.S.C. §112, for failure to provide an enabling description. Applicants have submitted new claims 42-45, 50, 51, 53 and 54 which recite the disclosed nucleic acid sequences and nucleic acid molecules encoding the